KYTX

$8.08+$0.03 (+0.37%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$497.8M

62M shares

52-week range

$3.27 – $13.67

46% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change$-21.92

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$13M	+87.5%	$-2.87	$-3.07–$-2.67	—	5
2027	$18M	+40.3%	$-2.94	$-3.33–$-2.38	—	5
2028	$53M	+203.2%	$-2.39	$-2.87–$-1.69	—	3
2029	$175M	+228.3%	$-3.65	$-6.93–$-1.46	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-12	$-0.68	$-0.63	+7.1%
2026-05-12	$-0.75	$-0.66	+12.0%
2026-03-26	$-0.84	$-0.80	+5.3%
2025-11-12	$-0.97	$-0.85	+12.4%
2025-08-12	$-1.00	$-0.97	+3.0%
2025-05-13	$-1.21	$-1.03	+14.9%
2025-03-27	$-0.87	$-0.88	-1.1%
2024-11-13	$-0.77

DCF fair valuemodel estimate

Intrinsic value

$2.04

Price

$8.08

Implied downside

-75%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
KYTXKyverna Therapeutics, Inc.	$8.08	+0.37%	$491M	—
ALLOAllogene Therapeutics, Inc.	$1.98	-4.35%	$683M	—
AVIRAtea Pharmaceuticals, Inc.	$5.07	+0.20%	$406M	—
CABACabaletta Bio, Inc.	$2.71	-4.91%	$442M	—
CAPRCapricor Therapeutics, Inc.	$4.21	+0.48%

Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

www.kyvernatx.com

Employees: 149
IPO / List date: Feb 8, 2024
HQ: EMERYVILLE, CA

Held by traders on TradeandTell

No one on the platform currently holds KYTX.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	367,492	$3.2M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded KYTX yet.

$KYTX chatter on StockTwits

Zack@ZackInvest0081d
$KYTX Tape doesn't reflect returned shares. Pretty garbage movement today on low volume.
View on StockTwits ↗
Derrick@TheRealiSwagBullish2d
@hummer2277 @blocktrade $KYTX is now a three RMAT nueroimmunology platform that is more than well positioned for success thanks to Elevate providing even more stability from a derisk standpoint. I'll be adding on further pullbacks. Love what i see here
View on StockTwits ↗
Harry@HarryScrotmmm2d
$KYTX not great at reading these reports but it looks like they only have 39 million cash on hand . They added some shares and their assets have to be the atm. ??
View on StockTwits ↗
blocktrade@blocktrade2d
$KYTX traded 9 shares after hours.
View on StockTwits ↗
Derrick@TheRealiSwagBullish2d
$KYTX company looks extremely undervalued now has plenty to discuss tomorrow for ER, update on trial, funds just scratching the surface. With having KITE's former management personnel positioned here, I remain quite optimistic re: its future of success $XBI $NVO $SPY
View on StockTwits ↗
Derrick@TheRealiSwagBullish2d
@TooMuchFinesse focusing on $KYTX and $ELVN currentlyas well as EDGE
View on StockTwits ↗
Derrick@TheRealiSwagBullish2d
@frankinsense69 Yes $KYTX is indeed a diamond in the rough, she'll be walked down post ER come tomorrow and will be a screaming strong buy. This management team ( former KITE personnel) is top notch and proven successful
View on StockTwits ↗
Frank n. Beans@frankinsense693d
$IMMX SYSTEMIC SCLEROSIS DD — credit to Mungermind for uncovering this trail. Systemic sclerosis/scleroderma is a rare, potentially fatal autoimmune disease in which abnormal antibodies drive blood-vessel damage and progressive scarring of the skin, lungs, heart and kidneys. There is NO cure. Current care primarily consists of chronic immunosuppression—mycophenolate, cyclophosphamide or off-label rituximab—plus tocilizumab/nintedanib for lung disease, organ-specific drugs and high-risk stem-cell transplantation for select severe patients. CAR-T competition validates the opportunity: 🔥 $CABA rese-cel: 5/6 patients reached rCRISS-25 and 4/6 reached rCRISS-50 🔥 $KYTX: Phase 1/2 KYV-101 trial 🔥 $NVS: randomized Phase 2 CAR-T trial versus rituximab Most competing programs target CD19 on B cells. Here is the overlooked IMMX angle: HBI0101 = NXC-201, and the autoimmune study was funded by Immix. NXC-201 targets BCMA on the deeper plasma-cell “antibody factories” responsible for producing destructive autoantibodies. In the peer-reviewed report: 🔥 ALL 3 systemic-sclerosis patients improved in skin involvement and disease-activity measures 🔥 Lupus activity fell to ZERO in 2/3 patients and to 4 in the third 🔥 No ICANS/neurotoxicity across all 6 patients 🔥 Early safety was considered acceptable Approximately 88,000 Americans have systemic sclerosis. If only 10% of that population ultimately became eligible for CAR-T, that would represent roughly 8,800 U.S. patients. At an illustrative $300K–$500K per one-time treatment, the initial prevalent opportunity alone could approach $2.6B–$4.4B—before new patients and international markets. Scleroderma has not officially been confirmed as IMMX’s lead autoimmune indication. But the human results, expanding 120-patient autoimmune basket trial, Sheba activity and IMMX’s promise of “initial clinical data in other serious diseases” make this far more than a laboratory theory. AL amyloidosis could prove NXC-201. Autoimmune disease could reveal the platform. 🔥🚀
View on StockTwits ↗
Joshua D@HeavyFtBullish3d
$KYTX Car-T the future for all autoimmune disorders
View on StockTwits ↗
NOT INV ADVICE@bernardbaruch3d
$KYTX I’m out I had to trade again to defend a core position that got a speed bump. GLTA I hope to be back. Stock has been very kind to me on trading. Great narrative too.
View on StockTwits ↗
Christoph@RitschierBullish3d
$KYTX Recently, there was a big article in the German newspaper FAZ (which ranks similarly to the NYT). https://www.faz.net/aktuell/wissen/medizin-ernaehrung/heilung-durch-car-t-zellen-sie-koennen-wieder-leben-201069344.html CAR-T cells in autoimmune diseases seem to be gaining broad public recognition. I liked that. There were some miracle stories in that article. What's interesting: Prof. Dr. Schett and Uni Erlangen are at the center of the article. I learned that the institute is a key researcher in the field and Schett is kind of its mastermind. Awards and publications tell the story. Since I am fairly new to Kyverna, I also just learned he was on Kyverna's scientific advisory board. Does anybody know if he's still in that function? And, oh ;-), in the article, Kyverna’s treatment for Stiff-Person Syndrome gets mentioned indirectly as probably the worldwide first approval for CAR-T cells in autoimmune disease: 'Approval by the US FDA is apparently just around the corner.'
View on StockTwits ↗
Derrick@TheRealiSwagBullish6d
$KYTX added a few today and next week will go much heavier, timing is right and so is the pricing. This is a gem and game changer in the making ⏳⌛️ $XBI $LLY $SPY
View on StockTwits ↗
Kenny@kenny916556d
$KYTX Lowest volume in a while
View on StockTwits ↗
Antzelo1234@ak123456790Aug 6
$KYTX Big funds are accumulating slowly until q4 when it pops hard ! Until then the price will be steady between 7-9
View on StockTwits ↗
The Legendary Mayor@BioRichBullishAug 5
$SABS, $KYTX, $GUTS, $SGP and $TLSA continue to be my wake up and "Did we get bought?" Bios. Always seems to be the sleepers. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.